Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Description for laymen
JSON Data
{
"short_title": "PRISM-MEL-301 (IMC-F106C-301)",
"data_mode": "900",
"data_mode_number": "000002403",
"official_title": "Eine randomisierte kontrollierte Phase-III-Studie zu IMC-F106C plus Nivolumab im Vergleich zu Nivolumab-Schemen bei HLA A*02:01-positiven Teilnehmern mit zuvor unbehandeltem fortgeschrittenem Melanom (PRISM-MEL-301)",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": "2023-505306-42",
"general_contact_email": "oncostudien.dermatologie@ukdd.de",
"general_contact_phone": "+49 351-45819782",
"hauptpruefer_dd_name": "Prof. Dr. med. Friedegund Meier",
"description_laie_de": "Eine randomisierte kontrollierte Phase-III-Studie zu IMC-F106C plus Nivolumab im Vergleich zu Nivolumab-Schemen bei HLA A*02:01-positiven Teilnehmern mit zuvor unbehandeltem fortgeschrittenem Melanom (PRISM-MEL-301)",
"description_laie_en": null,
"description_expert_de": null,
"description_expert_en": "A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "III",
"main_cat_id": 5,
"sub_cat_id": 35
}
